ClearOne, Inc. (NASDAQ:CLRO) experienced a dramatic surge on Tuesday, with shares climbing 48% to $10.36 in midday trading. The sharp move followed a July 6 SEC filing that provided more specifics on the company's planned merger with Cortigent, Inc., a subsidiary of Vivani Medical (NASDAQ:VANI). The filing revealed key details about share counts and financing arrangements, driving intense trading activity.
Trading volume reached 41.4 million shares, nearly 48 times ClearOne's listed float of 0.87 million shares. This extraordinary turnover reflects the market's reaction to the merger news, as investors scrambled to adjust positions. The stock fluctuated between $6.30 and $12.14 during the session, highlighting the volatility surrounding the announcement.
Merger Details and Share Structure
According to the July 6 Form 8-K, ClearOne reached an agreement on July 1 to merge its subsidiary into Cortigent, which will become a wholly owned unit of ClearOne. Vivani Medical is set to receive 12.5 million ClearOne shares as part of the transaction. The deal requires $10 million to $15 million in financing, which will be raised through the issuance of 2.5 million to 5.0 million units, each consisting of a ClearOne share and a warrant to purchase an additional share at $10.00 for six months.
Based on ClearOne's 2.675 million shares outstanding as of May 15, the combined entity could have between 18.5 million and 21 million shares outstanding, excluding Cortigent options and financing warrants. At the current price of $10.36, this implies an equity value of $192 million to $218 million, far above ClearOne's $28.7 million market cap before the merger announcement.
Ownership and Future Trading
ClearOne shareholders are expected to own approximately 12.7% to 14.4% of the merged company, while Vivani will hold 59.4% to 67.5%. Upon completion, the company plans to rename itself Cortigent Holdings, Inc. and trade under the ticker "CRGT" on Nasdaq. ClearOne board chair Eric Robinson expressed confidence in Cortigent's mission, stating that the planned financing should provide "a strong foundation" for the combined firm.
Cortigent CEO Jonathan Adams noted that the financing will accelerate development of products, including the Orion artificial vision device and a system aimed at restoring arm and hand mobility after stroke. The deal still requires shareholder approval, Nasdaq listing approval, and the completion of financing. However, ClearOne noted that holders of at least 50.1% of its common stock have signed voting support agreements, reducing some risk.
Market Implications
The rally has boosted ClearOne's share price ahead of the financing, which is set to close alongside the merger. The $10.00 warrant price is now close to being in the money, adding further interest for investors. The thin float has amplified the move, with the stock turning over nearly 48 times its available shares. This suggests that the price action is being driven by a combination of speculative demand and supply constraints.
ClearOne, previously known for conferencing products, has been transitioning away from that business. Last year, it sold assets to Biamp Systems but retained its public company structure. Former CEO Derek Graham emphasized that ClearOne would "continue to exist as a public company" even after the asset sale, setting the stage for this merger. The Cortigent deal represents a significant pivot, with the combined entity focusing on medical devices for vision and mobility restoration.
